Related Experiment Videos

[Cardiohemodynamics and microcirculation in patients with ischemic heart disease undergoing beta-adrenergic receptor

Vrachebnoe Delo
|February 1, 1990
PubMed

Insights

Anaprilin may worsen angina in middle-aged patients with coronary atherosclerosis. Nonachlazin can reduce angina but requires high physical tolerance, impacting treatment strategies for ischemic heart disease.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ischemic heart disease (IHD) involves coronary artery narrowing.
  • Beta-adrenodependent vasodilation may be impaired in IHD patients.

Purpose of the Study:

  • To evaluate the effects of anaprilin and nonachlazin on IHD patients.
  • To assess drug impact on clinical course and hemodynamics.

Main Methods:

  • Study included 76 IHD patients with 50-75% coronary stenosis.
  • Coronography was used to assess stenosis.
  • Clinical and hemodynamic effects of anaprilin and nonachlazin were analyzed.

Main Results:

  • Anaprilin may increase angina attack frequency in middle-aged patients with initial coronary atherosclerosis.
  • Nonachlazin reduces angina manifestations.
  • Nonachlazin use is limited to patients with high physical load tolerance.

Conclusions:

  • Anaprilin's use requires caution in specific IHD patient groups.
  • Nonachlazin offers angina relief but has specific patient selection criteria.
  • Individualized treatment is crucial for managing ischemic heart disease.

Related Concept Videos